WEBVTT - Stopping HIV Without a Vaccine

0:00:15.356 --> 0:00:23.956
<v Speaker 1>Pushkin. So I'm curious in your own life when you

0:00:24.036 --> 0:00:29.196
<v Speaker 1>first became aware of HIV and AIDS.

0:00:29.556 --> 0:00:34.116
<v Speaker 2>Oh gosh, this is a great question to start interview.

0:00:35.396 --> 0:00:41.036
<v Speaker 2>I am fifty I did one, so I do remember.

0:00:41.076 --> 0:00:44.036
<v Speaker 2>I remember the first news stories as a you know,

0:00:44.036 --> 0:00:49.396
<v Speaker 2>as a child. It's also been a driver of everything

0:00:49.396 --> 0:00:51.076
<v Speaker 2>I've worked on and wanted to work on.

0:00:51.716 --> 0:00:56.236
<v Speaker 1>I am also fifty one, coincidentally, and I you know,

0:00:56.476 --> 0:00:59.916
<v Speaker 1>I vaguely remember the world before HIV and AIDS. I

0:00:59.996 --> 0:01:02.436
<v Speaker 1>also remember, and I'm sure you remember this too, like

0:01:02.956 --> 0:01:06.276
<v Speaker 1>coming of age at a time when if you got AIDS,

0:01:06.276 --> 0:01:08.716
<v Speaker 1>you died, and you could get it from having sex.

0:01:09.156 --> 0:01:10.036
<v Speaker 2>Uh.

0:01:10.196 --> 0:01:13.436
<v Speaker 1>To me, that's the that's the big imprint it left

0:01:13.476 --> 0:01:16.876
<v Speaker 1>on my own you know, narrowly, narcissistically on my own life.

0:01:17.116 --> 0:01:20.356
<v Speaker 2>Yes, so much fear, right, so much, so much death,

0:01:21.316 --> 0:01:26.996
<v Speaker 2>so much destruction, destruction of potential, and so much fear

0:01:27.076 --> 0:01:32.316
<v Speaker 2>and surgainly for a generation to have fear and sex

0:01:32.596 --> 0:01:38.356
<v Speaker 2>so coupled with each other, so intertwined. But it's always

0:01:38.396 --> 0:01:41.516
<v Speaker 2>driven me to to to end HIV is to be

0:01:41.596 --> 0:01:44.956
<v Speaker 2>able for you know, there to be a generation who

0:01:45.036 --> 0:01:48.036
<v Speaker 2>didn't have that cloud of fear in their lives.

0:01:54.156 --> 0:01:56.556
<v Speaker 1>I'm Jacob Goldstein and this is What's Your Problem, the

0:01:56.596 --> 0:01:58.596
<v Speaker 1>show where I talk to people who are trying to

0:01:58.676 --> 0:02:03.316
<v Speaker 1>make technological progress. My guest today is Jared Bayton. He's

0:02:03.396 --> 0:02:08.356
<v Speaker 1>senior vice president in virology Achillead Sciences. Jared's problem is this,

0:02:09.156 --> 0:02:11.916
<v Speaker 1>in a world without a vaccine, how do you prevent

0:02:11.996 --> 0:02:17.756
<v Speaker 1>people from getting HIV. It's been clear for years that

0:02:17.836 --> 0:02:21.756
<v Speaker 1>taking a daily pill dramatically reduces the risk of getting HIV,

0:02:22.356 --> 0:02:25.116
<v Speaker 1>but as you'll hear, the vast majority of people who

0:02:25.156 --> 0:02:28.516
<v Speaker 1>are at high risk for getting HIV just don't take

0:02:28.556 --> 0:02:32.236
<v Speaker 1>a pill every day. Now, Jared and his colleagues are

0:02:32.236 --> 0:02:35.516
<v Speaker 1>working on a new option, a drug called leni kapavir

0:02:35.716 --> 0:02:38.716
<v Speaker 1>that you get as a shot once every six months.

0:02:39.036 --> 0:02:42.036
<v Speaker 1>The drug has not yet been approved to prevent HIV,

0:02:42.596 --> 0:02:45.316
<v Speaker 1>but there have been some really compelling results from a

0:02:45.316 --> 0:02:48.556
<v Speaker 1>couple big clinical trials. There's a lot that's interesting in

0:02:48.596 --> 0:02:51.396
<v Speaker 1>the show today, how medicine only works if it meets

0:02:51.396 --> 0:02:54.116
<v Speaker 1>people where they are, and how what seemed like a

0:02:54.156 --> 0:02:57.076
<v Speaker 1>big problem for Lena kapavir may turn out to be

0:02:57.276 --> 0:03:00.476
<v Speaker 1>the key to its success. But we started with Jared's

0:03:00.476 --> 0:03:02.796
<v Speaker 1>own career, which tracks a lot of the history of

0:03:02.996 --> 0:03:06.516
<v Speaker 1>HIV and AIDS and the emergence of drugs that can

0:03:06.596 --> 0:03:10.556
<v Speaker 1>prevent people from becoming infected. So when do you decide

0:03:10.636 --> 0:03:16.836
<v Speaker 1>to make fighting HIV your career.

0:03:17.316 --> 0:03:20.156
<v Speaker 2>When I went to graduate school and medical school, I

0:03:20.156 --> 0:03:22.876
<v Speaker 2>was when I decided to work on HIV that I

0:03:22.956 --> 0:03:26.796
<v Speaker 2>wanted to do health work that was meaningful to the world.

0:03:26.876 --> 0:03:29.716
<v Speaker 2>That was that it was and it was immediately actionable.

0:03:30.356 --> 0:03:33.116
<v Speaker 2>As a graduate student during medical school, I lived and

0:03:33.156 --> 0:03:38.036
<v Speaker 2>worked on HIV prevention in Kenya. Obviously before there was

0:03:39.116 --> 0:03:44.436
<v Speaker 2>medicine for prevention, and I remember very well, even before

0:03:44.516 --> 0:03:46.836
<v Speaker 2>there was very good testing. I was a strain of

0:03:46.836 --> 0:03:50.636
<v Speaker 2>thought at the time that testing was too scary to

0:03:50.676 --> 0:03:52.356
<v Speaker 2>do because there was nothing to be done.

0:03:52.796 --> 0:03:53.236
<v Speaker 1>Wow.

0:03:53.316 --> 0:03:55.916
<v Speaker 2>I certainly had other doctors say that to me. I

0:03:56.156 --> 0:04:01.956
<v Speaker 2>the hospital that I worked in Kenya, the only testing

0:04:02.196 --> 0:04:04.796
<v Speaker 2>that was done was so people could stop spending money

0:04:04.876 --> 0:04:05.836
<v Speaker 2>on their family members.

0:04:05.996 --> 0:04:08.476
<v Speaker 1>Oh my god, So meaning, oh, don't spend any money

0:04:08.516 --> 0:04:11.396
<v Speaker 1>on them. They have HIV, They're going to die. That's

0:04:11.476 --> 0:04:12.836
<v Speaker 1>why they were doing the tests.

0:04:13.036 --> 0:04:15.596
<v Speaker 2>Yeah, someone in the hospital extraordinarily sick. Let's do an

0:04:15.676 --> 0:04:18.596
<v Speaker 2>HIV test. Okay, you can stop spending money. Jesus and

0:04:18.796 --> 0:04:22.236
<v Speaker 2>then really importantly, I remember when medicines came. I remember

0:04:22.276 --> 0:04:25.476
<v Speaker 2>when medicines came. I remember when I remember very well

0:04:25.476 --> 0:04:28.356
<v Speaker 2>when the coffin makers who would work in the street

0:04:28.396 --> 0:04:30.276
<v Speaker 2>outside the hospital start going out of.

0:04:30.236 --> 0:04:34.756
<v Speaker 3>Business, the coffin makers, the coffin makers, yep, holy yahkah,

0:04:36.676 --> 0:04:42.636
<v Speaker 3>which gosh, the Kenya's prevalence maybe at fifteen percent or

0:04:42.676 --> 0:04:44.956
<v Speaker 3>something like that at some point, and it's.

0:04:44.756 --> 0:04:50.356
<v Speaker 2>Not much lower to be able to see in that

0:04:50.396 --> 0:04:53.236
<v Speaker 2>country and other countries what medicines can do. And that's

0:04:53.276 --> 0:04:56.396
<v Speaker 2>actually that's what drove a lot of signs. I've always done,

0:04:56.436 --> 0:05:00.116
<v Speaker 2>is HIV prevention and then HIV treatment, but making medicines

0:05:00.156 --> 0:05:02.556
<v Speaker 2>that make a difference in people's lives, and like what

0:05:02.956 --> 0:05:06.756
<v Speaker 2>good medicines did for HIV care here in the US

0:05:06.796 --> 0:05:09.316
<v Speaker 2>where I live from, in many parts of Africa where

0:05:09.316 --> 0:05:14.876
<v Speaker 2>I've worked, and how fundamentally transformed, how socially transformative, how

0:05:14.956 --> 0:05:20.636
<v Speaker 2>something risked really destroying in fraction societies, and how good

0:05:20.676 --> 0:05:23.716
<v Speaker 2>science was able to arrest that in averse.

0:05:23.756 --> 0:05:28.156
<v Speaker 1>Then so okay, so that's what's happening, you know, around

0:05:28.156 --> 0:05:31.476
<v Speaker 1>the turn of this century. And then there's this new

0:05:31.556 --> 0:05:34.956
<v Speaker 1>idea that comes along after that right, and that is

0:05:35.516 --> 0:05:38.516
<v Speaker 1>what if we can use these drugs to prevent people

0:05:38.556 --> 0:05:42.516
<v Speaker 1>at high risk from getting HIV in the first place. Right,

0:05:42.596 --> 0:05:45.756
<v Speaker 1>This idea called prep Where does that come from?

0:05:46.276 --> 0:05:48.596
<v Speaker 2>So this idea of prep pre exposure, prople axis, you

0:05:48.596 --> 0:05:51.556
<v Speaker 2>take a medicine. By having that medicine, your bloodstreams, your

0:05:51.556 --> 0:05:55.156
<v Speaker 2>tissues or whatever, you if you expose to the virus,

0:05:55.396 --> 0:06:00.676
<v Speaker 2>it doesn't take hold. Yeah, and the idea of propyle

0:06:00.676 --> 0:06:05.036
<v Speaker 2>axis is not totally novel in infectious diseases. If you've

0:06:05.036 --> 0:06:07.436
<v Speaker 2>ever traveled to a place with malaria, you've probably taken

0:06:07.476 --> 0:06:10.996
<v Speaker 2>a malaria propyle axis that kind of idea, But they

0:06:11.116 --> 0:06:15.116
<v Speaker 2>do prep for HIV was super surprising at the time.

0:06:15.236 --> 0:06:15.516
<v Speaker 1>Huh.

0:06:15.556 --> 0:06:18.836
<v Speaker 2>You have to have a medicine that would work to

0:06:18.876 --> 0:06:22.756
<v Speaker 2>prevent HIV and HIV is very transmissible, so to avert

0:06:23.596 --> 0:06:26.916
<v Speaker 2>infection would be a high bar. And then it has

0:06:26.916 --> 0:06:30.516
<v Speaker 2>to be medicine itself that's very well tolerated, very safe

0:06:30.556 --> 0:06:34.476
<v Speaker 2>because you're it would be given to healthy individuals who

0:06:34.516 --> 0:06:38.076
<v Speaker 2>don't have affection, and the societal medical tolerance for side

0:06:38.076 --> 0:06:41.436
<v Speaker 2>effects for treating HIV, just like treating any really serious

0:06:41.556 --> 0:06:44.916
<v Speaker 2>dead latencies, is different than but for preventing.

0:06:44.516 --> 0:06:46.676
<v Speaker 1>It, sure, it has to be lower risk. Right, if

0:06:46.716 --> 0:06:48.756
<v Speaker 1>you already have HIV and you're going to die, you're

0:06:48.796 --> 0:06:51.636
<v Speaker 1>willing to take a right medicine that has pretty severe

0:06:51.676 --> 0:06:55.036
<v Speaker 1>side effects, whereas if you're healthy, you're not going to

0:06:55.116 --> 0:06:58.916
<v Speaker 1>take some really harsh, risky drug just in case.

0:06:59.156 --> 0:07:03.276
<v Speaker 2>Exactly exactly right and unfortunately for treating HIV. Just for

0:07:03.756 --> 0:07:06.516
<v Speaker 2>your listeners, like the complexity and the side effects of

0:07:06.556 --> 0:07:09.476
<v Speaker 2>the medicines from the late nineties and two thousand have

0:07:10.036 --> 0:07:12.836
<v Speaker 2>changed dramatically in the last couple of decades, and so

0:07:12.956 --> 0:07:15.756
<v Speaker 2>that most people these days actually take a single pill

0:07:16.076 --> 0:07:21.396
<v Speaker 2>once a day, extremely well tolerated, and live what's expected

0:07:21.436 --> 0:07:23.036
<v Speaker 2>to be a full lifespan lived as long as someone

0:07:23.036 --> 0:07:26.116
<v Speaker 2>who doesn't have HIV and are on infections. So just

0:07:26.116 --> 0:07:29.276
<v Speaker 2>so people know what's changing. But in early two thousands,

0:07:30.076 --> 0:07:31.436
<v Speaker 2>medicine still had side effects.

0:07:31.436 --> 0:07:33.116
<v Speaker 1>Were you working on PREP at this time?

0:07:33.316 --> 0:07:36.116
<v Speaker 2>I worked on one of the two trials that formed

0:07:36.236 --> 0:07:40.796
<v Speaker 2>the registrational package of PREP, one in mostly gave men

0:07:40.876 --> 0:07:45.796
<v Speaker 2>and some transgender individuals, and then one in heterosexual individuals,

0:07:46.476 --> 0:07:49.596
<v Speaker 2>women and men, And that was the second one was

0:07:49.596 --> 0:07:51.676
<v Speaker 2>the study that I worked on with collaborators from all

0:07:51.716 --> 0:07:54.836
<v Speaker 2>over the world. And based in Kenyan. You gotta it

0:07:54.996 --> 0:07:59.116
<v Speaker 2>was almost five thousand couples where one person didn't have

0:07:59.236 --> 0:08:00.196
<v Speaker 2>HIV and the other one did.

0:08:01.236 --> 0:08:03.556
<v Speaker 1>So that's a very high risk setting, very.

0:08:03.516 --> 0:08:07.036
<v Speaker 2>Higher setting, and also setting where there was tremendous motivation

0:08:07.716 --> 0:08:10.436
<v Speaker 2>to have a different life experien for the couple it was.

0:08:11.036 --> 0:08:13.196
<v Speaker 2>It was a really remarkable time because there was lots

0:08:13.196 --> 0:08:15.156
<v Speaker 2>of questions where the park would work at all. There

0:08:15.156 --> 0:08:16.716
<v Speaker 2>was not a question where it could be safe enough

0:08:17.276 --> 0:08:22.316
<v Speaker 2>and go to the trials demonstrated both safety and HIV protection.

0:08:22.996 --> 0:08:26.036
<v Speaker 2>Protection that was dependent on people taking it. Like all medicines,

0:08:26.076 --> 0:08:28.716
<v Speaker 2>medicines only work if you take them, and there are

0:08:28.716 --> 0:08:31.316
<v Speaker 2>all kinds of different motivations to take something, predict something

0:08:31.356 --> 0:08:33.956
<v Speaker 2>that's every day, and some people really succeed and some

0:08:33.996 --> 0:08:36.636
<v Speaker 2>people really struggle. As you can access.

0:08:36.396 --> 0:08:40.836
<v Speaker 1>So you are, they're setting up the next turn in

0:08:40.916 --> 0:08:43.076
<v Speaker 1>our story, which is the new drug we are here

0:08:43.116 --> 0:08:48.396
<v Speaker 1>to talk about, right, But let's just do that for

0:08:48.436 --> 0:08:52.236
<v Speaker 1>a minute more, because as you said that the drugs

0:08:52.276 --> 0:08:56.396
<v Speaker 1>people can take to prevent getting HIV have gotten easier

0:08:56.436 --> 0:09:00.716
<v Speaker 1>to take and better tolerated. And you know, if you

0:09:00.796 --> 0:09:02.556
<v Speaker 1>can take one pill a day and you're in a

0:09:02.596 --> 0:09:05.316
<v Speaker 1>high risk setting and that means you have a profoundly

0:09:05.316 --> 0:09:09.876
<v Speaker 1>lower risk of getting HIV. Like, what's the problem? Like

0:09:09.916 --> 0:09:12.116
<v Speaker 1>I feel like, great work, thank you for doing that

0:09:12.156 --> 0:09:14.796
<v Speaker 1>good work, and like it seems like you're there.

0:09:18.196 --> 0:09:20.596
<v Speaker 2>I'm sure there were moments where I thought, it seems

0:09:20.596 --> 0:09:23.316
<v Speaker 2>like we're there. This seems obvious to me as well. Yeah,

0:09:23.396 --> 0:09:27.796
<v Speaker 2>I remember well the first day. Its actually years after

0:09:28.156 --> 0:09:32.756
<v Speaker 2>the first medication for PREP was approved, where it had

0:09:32.756 --> 0:09:37.116
<v Speaker 2>never been something like this hadn't been rolled out in clinics,

0:09:37.116 --> 0:09:41.156
<v Speaker 2>so like people doctors didn't have the conversation pieces to

0:09:41.196 --> 0:09:43.836
<v Speaker 2>talk with this, patients or individuals who wanted PREP didn't

0:09:44.196 --> 0:09:48.796
<v Speaker 2>always have heard about it or didn't have the practice

0:09:48.836 --> 0:09:52.876
<v Speaker 2>and asking for it. And it was slow. It was

0:09:52.916 --> 0:09:55.636
<v Speaker 2>slow going, slow going in this country, slow going around the.

0:09:55.596 --> 0:09:59.516
<v Speaker 1>World, slow going meaning people just didn't take it that much.

0:09:59.556 --> 0:10:02.156
<v Speaker 1>Healthy people didn't want to take a pill every day.

0:10:02.316 --> 0:10:04.356
<v Speaker 2>Yeah, I was like, yes, this is hard, like new

0:10:04.476 --> 0:10:07.996
<v Speaker 2>innovations and health are hard because none of us make

0:10:08.076 --> 0:10:11.436
<v Speaker 2>health decisions, or at least I think most of us.

0:10:11.436 --> 0:10:13.436
<v Speaker 2>Most of us do not make health decisions just because

0:10:13.476 --> 0:10:17.116
<v Speaker 2>someone tells us to or because the science is really excellent.

0:10:17.156 --> 0:10:18.876
<v Speaker 2>We make health decisions because we think it's going to

0:10:19.236 --> 0:10:21.316
<v Speaker 2>be meaningful for us. So whether that's like what we

0:10:21.436 --> 0:10:24.196
<v Speaker 2>eat or going to gym, or like what we buy

0:10:24.236 --> 0:10:28.156
<v Speaker 2>off Instagram or whatever else for our health, Like, we

0:10:28.236 --> 0:10:30.716
<v Speaker 2>make those decisions because we think it's meaningful for us.

0:10:30.716 --> 0:10:33.116
<v Speaker 2>And something like PREP, which can be extorted and meaningful,

0:10:33.236 --> 0:10:35.556
<v Speaker 2>it has to be extortedly meaningful for someone to want

0:10:35.596 --> 0:10:38.556
<v Speaker 2>to make the effort to go to get it and

0:10:38.636 --> 0:10:42.116
<v Speaker 2>to continue it. There are many many people who take

0:10:42.116 --> 0:10:44.636
<v Speaker 2>PREP every single day. It fits into their lives. It

0:10:44.636 --> 0:10:47.676
<v Speaker 2>brings benefit, and it brings meeting and they can make

0:10:47.716 --> 0:10:51.156
<v Speaker 2>it workable within their lives. And then there have been

0:10:51.516 --> 0:10:55.396
<v Speaker 2>many people who have tried and stopped or not tried

0:10:55.436 --> 0:10:58.676
<v Speaker 2>at all. And that's like setting up for my rest

0:10:58.716 --> 0:11:04.076
<v Speaker 2>for our discussion. Just because you have something that works

0:11:04.436 --> 0:11:08.516
<v Speaker 2>for some people, that airing that bottle home or it

0:11:08.516 --> 0:11:12.116
<v Speaker 2>could be found by an aunt, partner or brother or

0:11:12.116 --> 0:11:19.556
<v Speaker 2>whatever is too much, too much disclosure, too much revealing.

0:11:20.236 --> 0:11:23.876
<v Speaker 1>It means you're having sex, probably right, yeah.

0:11:23.556 --> 0:11:27.756
<v Speaker 2>Exactly, Or the complexity of the of taking something every

0:11:27.836 --> 0:11:31.396
<v Speaker 2>day when you've got two jobs and three kids or

0:11:31.396 --> 0:11:35.076
<v Speaker 2>whatever the things are that for something that you don't

0:11:35.076 --> 0:11:36.196
<v Speaker 2>really want to think about every day.

0:11:36.716 --> 0:11:40.116
<v Speaker 1>Yeah, it's a very good qualitative description. Is there a

0:11:40.236 --> 0:11:44.356
<v Speaker 1>quantitative piece like, have you estimated the population that you

0:11:44.396 --> 0:11:46.836
<v Speaker 1>know might be relevant but doesn't want to take a

0:11:46.836 --> 0:11:48.036
<v Speaker 1>pill every day in the first place.

0:11:48.316 --> 0:11:52.276
<v Speaker 2>Yeah, In the US, CC is estimated that maybe about

0:11:52.276 --> 0:11:54.956
<v Speaker 2>a third of the people who would most benefit from

0:11:54.996 --> 0:11:57.596
<v Speaker 2>taking PREP, not even like benefit at all, but like

0:11:57.676 --> 0:12:00.996
<v Speaker 2>most benefit from taking PREP are taking it sort of

0:12:00.996 --> 0:12:02.676
<v Speaker 2>today we are taking it day to day.

0:12:02.716 --> 0:12:05.756
<v Speaker 1>Wait, one third of the people who are at highest

0:12:05.876 --> 0:12:08.596
<v Speaker 1>risk for getting HIV are taking it. So two thirds

0:12:08.596 --> 0:12:09.796
<v Speaker 1>of the people are.

0:12:09.556 --> 0:12:12.596
<v Speaker 2>Not exactly so, a third r a third arth, two

0:12:12.596 --> 0:12:13.116
<v Speaker 2>thirds are not.

0:12:13.716 --> 0:12:19.316
<v Speaker 1>So okay, So there is this idea that PREP is great,

0:12:19.356 --> 0:12:21.996
<v Speaker 1>but most people who could most benefit from it don't

0:12:22.036 --> 0:12:26.516
<v Speaker 1>take it. One thought as well, if instead of having

0:12:26.596 --> 0:12:28.996
<v Speaker 1>to take a pill every day, it was less frequent,

0:12:30.156 --> 0:12:32.596
<v Speaker 1>simple behavioral thing, maybe people would do it more often.

0:12:32.676 --> 0:12:35.036
<v Speaker 1>And so so there's this search for a for a

0:12:35.076 --> 0:12:37.956
<v Speaker 1>new drug that is longer lasting, right, that you in

0:12:37.996 --> 0:12:40.796
<v Speaker 1>fact have found spoiler alert, But tell me about the

0:12:41.116 --> 0:12:41.956
<v Speaker 1>search for that drug.

0:12:42.636 --> 0:12:47.276
<v Speaker 2>The idea was that HIV has a structural element called

0:12:47.356 --> 0:12:50.156
<v Speaker 2>it's capsid, where it encloses the nucleic acid of the

0:12:50.196 --> 0:12:52.236
<v Speaker 2>virus within the virus.

0:12:52.076 --> 0:12:54.436
<v Speaker 1>It's it's like it's the bag, right, It's the protein.

0:12:54.636 --> 0:12:58.556
<v Speaker 2>It's yeah, it's a protein coming. It's like a yeah.

0:12:58.356 --> 0:13:00.476
<v Speaker 2>And I always want to think it's stronger than the bag.

0:13:00.636 --> 0:13:01.956
<v Speaker 2>It's stronger than a bag.

0:13:02.036 --> 0:13:06.836
<v Speaker 1>It's like okay, it like akayas case flask okay, okay.

0:13:07.396 --> 0:13:09.836
<v Speaker 2>And that's the virus is coming into the cell that

0:13:09.956 --> 0:13:11.876
<v Speaker 2>opens and dumps the new class ass and out. So

0:13:11.916 --> 0:13:14.156
<v Speaker 2>the virus is infecting and when it leaves it encapsulates

0:13:14.156 --> 0:13:18.036
<v Speaker 2>the begin and floats away. And targeting that is particularly hard,

0:13:18.036 --> 0:13:21.716
<v Speaker 2>and the work on it began a dozen years before

0:13:22.196 --> 0:13:25.236
<v Speaker 2>took a dozen years from the work to start before

0:13:25.276 --> 0:13:27.316
<v Speaker 2>we've even tested any human being for the first time,

0:13:28.796 --> 0:13:34.236
<v Speaker 2>and four thousand molecules were synthesized and screened in test

0:13:34.236 --> 0:13:35.996
<v Speaker 2>tubes and animals, selling them other things to be able

0:13:36.036 --> 0:13:38.636
<v Speaker 2>to be able to bring forward one to be able

0:13:38.676 --> 0:13:41.116
<v Speaker 2>to test in human beings, which then became a lot

0:13:41.116 --> 0:13:41.556
<v Speaker 2>of capeer.

0:13:45.596 --> 0:13:46.916
<v Speaker 1>We'll be back in a minute.

0:13:56.796 --> 0:13:59.876
<v Speaker 2>A virus like HIV has a certain number of proteins

0:13:59.876 --> 0:14:03.116
<v Speaker 2>that make it function right and caps it had not

0:14:03.196 --> 0:14:06.036
<v Speaker 2>been targeted and as a result of a great question

0:14:06.076 --> 0:14:08.036
<v Speaker 2>to say, could we target this part of the virus

0:14:08.036 --> 0:14:10.956
<v Speaker 2>in a way that it's different. This is important for

0:14:11.116 --> 0:14:16.356
<v Speaker 2>HIV broadly because what has been the success of treating

0:14:16.436 --> 0:14:19.476
<v Speaker 2>HIV is being able to target the virus in multiple places,

0:14:20.676 --> 0:14:24.396
<v Speaker 2>in multiple components of its life cycle, and that is

0:14:24.476 --> 0:14:28.796
<v Speaker 2>what makes up a treatment cocktail for HIV. Multiple medications

0:14:29.316 --> 0:14:32.036
<v Speaker 2>usually the target different parts of the virus life cycle

0:14:32.116 --> 0:14:34.996
<v Speaker 2>at the same time, and from a safety point of view,

0:14:35.036 --> 0:14:38.076
<v Speaker 2>actually ones that are very specific to the virus itself

0:14:38.236 --> 0:14:43.756
<v Speaker 2>and don't have effects on us. And so a enzyme

0:14:43.796 --> 0:14:46.236
<v Speaker 2>that only the virus makes, or in this case, protein

0:14:46.276 --> 0:14:48.756
<v Speaker 2>protein interaction that only the virus has, is a great

0:14:48.996 --> 0:14:53.996
<v Speaker 2>target because there's nothing that looks like that in our

0:14:54.396 --> 0:14:55.276
<v Speaker 2>regular systems.

0:14:56.116 --> 0:14:58.836
<v Speaker 1>So basically that means people are likely to have fewer

0:14:58.876 --> 0:15:01.636
<v Speaker 1>side effects because our own cells aren't gonna be bothered.

0:15:02.076 --> 0:15:04.476
<v Speaker 1>So it seems like a promising target because it's this

0:15:04.556 --> 0:15:06.836
<v Speaker 1>weird thing that the virus does that we don't do.

0:15:07.596 --> 0:15:11.356
<v Speaker 1>And then drug researchers find this, this molecule, right, this

0:15:11.556 --> 0:15:14.756
<v Speaker 1>potential drug that will eventually be called len.

0:15:14.596 --> 0:15:15.276
<v Speaker 2>A cap of bear.

0:15:15.956 --> 0:15:18.796
<v Speaker 1>But but there's what seems like a problem with this

0:15:18.916 --> 0:15:21.556
<v Speaker 1>with this molecule, right, and the problem is that it's

0:15:21.636 --> 0:15:25.716
<v Speaker 1>not very soluble in water. It doesn't dissolve well in water.

0:15:26.196 --> 0:15:27.716
<v Speaker 1>Tell tell me about that part of it.

0:15:28.756 --> 0:15:31.796
<v Speaker 2>There people who work on it. Just sometimes you do

0:15:31.796 --> 0:15:33.436
<v Speaker 2>a lot of work to try to figure out the

0:15:33.476 --> 0:15:36.756
<v Speaker 2>best what's got the best attack on the virus itself

0:15:36.756 --> 0:15:38.876
<v Speaker 2>around the end time you're trying to target itself. And

0:15:38.916 --> 0:15:42.636
<v Speaker 2>then it's not particularly soluble problem because that like medicines

0:15:42.636 --> 0:15:45.996
<v Speaker 2>that we take through our mouth, for example, like most

0:15:45.996 --> 0:15:49.796
<v Speaker 2>medicine surge IVY need to dissolve an order for us

0:15:49.836 --> 0:15:52.436
<v Speaker 2>to absorb them. And actually a lot of work goes

0:15:52.476 --> 0:15:55.276
<v Speaker 2>into one one's doing drug development, and maybe you figure

0:15:55.276 --> 0:15:56.796
<v Speaker 2>out the thing that targets best, and then you figure

0:15:56.796 --> 0:15:58.756
<v Speaker 2>out how to modify it ever as best you can

0:15:59.196 --> 0:16:01.316
<v Speaker 2>to be able to absorb it, because if you can't

0:16:01.316 --> 0:16:02.996
<v Speaker 2>absorb it doesn't have an effect.

0:16:02.916 --> 0:16:05.516
<v Speaker 1>Right you want you want it to dissolve in water.

0:16:05.556 --> 0:16:07.716
<v Speaker 1>You want to take it and then it dissolves and

0:16:08.276 --> 0:16:10.956
<v Speaker 1>goes off into your correct exactly.

0:16:11.716 --> 0:16:16.116
<v Speaker 2>It's the tremendous advantage of Lena kaeper beer has been

0:16:16.556 --> 0:16:21.276
<v Speaker 2>for what it eventually became is that when it's formulated

0:16:21.276 --> 0:16:25.356
<v Speaker 2>as an injection, it forms a deepot of the drug,

0:16:25.476 --> 0:16:28.916
<v Speaker 2>well deposit of the drug that dissolves slowly over time

0:16:28.956 --> 0:16:31.236
<v Speaker 2>because it isn't immediately soluble.

0:16:31.316 --> 0:16:34.276
<v Speaker 1>And like, was there a moment when somebody sort of

0:16:34.356 --> 0:16:37.756
<v Speaker 1>just realized like, oh, this this bug could actually be

0:16:37.956 --> 0:16:40.236
<v Speaker 1>you know, like an amazing feature. You know the fact

0:16:40.276 --> 0:16:42.636
<v Speaker 1>that it's not soluble, like it might mean we could

0:16:42.676 --> 0:16:44.596
<v Speaker 1>give this drug to people and it would last a

0:16:44.636 --> 0:16:45.556
<v Speaker 1>really long time.

0:16:46.116 --> 0:16:47.996
<v Speaker 2>I don't think that there's an exact moment. I think

0:16:47.996 --> 0:16:51.476
<v Speaker 2>there's actually many moments along the way or a discovery

0:16:51.596 --> 0:16:54.516
<v Speaker 2>like this, it's what do we have? How do we

0:16:54.556 --> 0:16:56.716
<v Speaker 2>improve on that? Where could we get to? And I

0:16:56.716 --> 0:16:59.676
<v Speaker 2>think the I will tell you the very first testing

0:16:59.716 --> 0:17:01.876
<v Speaker 2>of lena caprier was not a six month injection.

0:17:02.516 --> 0:17:04.756
<v Speaker 1>So over time, a lot of whiteboards, a lot of

0:17:04.796 --> 0:17:07.956
<v Speaker 1>rooms full of people, you get to this idea of oh,

0:17:07.996 --> 0:17:10.436
<v Speaker 1>we could do this as an injection that lasts four

0:17:10.436 --> 0:17:11.236
<v Speaker 1>months and months.

0:17:11.516 --> 0:17:11.636
<v Speaker 3>Right.

0:17:11.956 --> 0:17:12.156
<v Speaker 2>Yeah.

0:17:12.396 --> 0:17:16.276
<v Speaker 1>So there's two big sort of pivotal trials that you run, right,

0:17:16.276 --> 0:17:17.036
<v Speaker 1>tell me about them.

0:17:17.316 --> 0:17:20.716
<v Speaker 2>It's actually an entire program called Purpose And there are

0:17:20.756 --> 0:17:22.516
<v Speaker 2>two trials, Purpose one in Purpose two.

0:17:23.156 --> 0:17:25.316
<v Speaker 1>What's the acronym you say, Purpose? I got to ask

0:17:25.356 --> 0:17:25.996
<v Speaker 1>you for the acronym.

0:17:26.076 --> 0:17:29.916
<v Speaker 2>Oh, no, so the actually that acronym really is really complicated.

0:17:31.036 --> 0:17:36.636
<v Speaker 2>It is not a clear pee you are, so, yeah, no, yeah,

0:17:36.636 --> 0:17:39.636
<v Speaker 2>I don't make these up. But the trials are run

0:17:39.676 --> 0:17:44.796
<v Speaker 2>across five continents, thousands of people, almost ten thousand people

0:17:44.796 --> 0:17:47.956
<v Speaker 2>in total. And the two trials Purpose one and two

0:17:48.756 --> 0:17:53.596
<v Speaker 2>were the trials that specifically are phase three pivotal trials

0:17:53.596 --> 0:17:55.596
<v Speaker 2>for testing whether something is safe and effective.

0:17:56.956 --> 0:17:57.876
<v Speaker 1>And what were the results?

0:17:58.836 --> 0:18:03.196
<v Speaker 2>Yeah, so Purpose one is among Allison girls and young

0:18:03.236 --> 0:18:08.156
<v Speaker 2>women in South Africa Uganda. It's almost five thousand people

0:18:08.196 --> 0:18:11.156
<v Speaker 2>in the trial who were either taking the daily pill

0:18:11.316 --> 0:18:14.196
<v Speaker 2>or taking the injection. And the among people who were

0:18:14.236 --> 0:18:17.476
<v Speaker 2>assigned the injection, zero infections occurred for the primary d

0:18:17.516 --> 0:18:19.876
<v Speaker 2>priant of the trial, which had never been seen before

0:18:19.916 --> 0:18:21.236
<v Speaker 2>for an HIV prevention trial.

0:18:21.756 --> 0:18:26.036
<v Speaker 1>So okay, so zero absolutely no. One of the two

0:18:26.116 --> 0:18:29.716
<v Speaker 1>thousand or so people who got lenni kapavir, none of

0:18:29.756 --> 0:18:32.556
<v Speaker 1>them got HIV in the control group. So they were

0:18:32.556 --> 0:18:36.956
<v Speaker 1>taking in the control group of the anti retroviral pills

0:18:36.996 --> 0:18:40.596
<v Speaker 1>that are standard. Now, how many of those people got HIV.

0:18:40.916 --> 0:18:44.276
<v Speaker 2>For people who are getting the control pill, which is

0:18:44.516 --> 0:18:48.876
<v Speaker 2>active prep, the approved active crap, sixteen out of about

0:18:48.916 --> 0:18:49.916
<v Speaker 2>one thousand.

0:18:51.076 --> 0:18:53.036
<v Speaker 1>So sixteen out of a thousand is kind of a lot.

0:18:53.196 --> 0:18:54.876
<v Speaker 1>This is like over the course of what a year.

0:18:54.916 --> 0:18:58.996
<v Speaker 2>Or something about a year a year follow and in

0:18:59.116 --> 0:19:02.956
<v Speaker 2>almost all the cases of the sixteen it's because invested

0:19:03.036 --> 0:19:06.756
<v Speaker 2>blood samples from those individuals they weren't using it, and

0:19:07.476 --> 0:19:11.196
<v Speaker 2>a testament to for some people how challenging it can

0:19:11.276 --> 0:19:15.316
<v Speaker 2>be to use something every day and how something that

0:19:15.756 --> 0:19:19.676
<v Speaker 2>injection twice a year for many people both could be

0:19:19.716 --> 0:19:23.396
<v Speaker 2>very effective, but also is something that they can make

0:19:23.436 --> 0:19:26.796
<v Speaker 2>workable because you can set it and not think about.

0:19:26.556 --> 0:19:31.916
<v Speaker 1>It, Okay, forget it. What's the other What was the

0:19:31.956 --> 0:19:33.796
<v Speaker 1>result of the second pivotal trial.

0:19:34.196 --> 0:19:37.996
<v Speaker 2>Yeah, the second pivotal trial was the more geographically diverse

0:19:38.556 --> 0:19:41.796
<v Speaker 2>group and was men, transgender women, and men and gender

0:19:41.836 --> 0:19:45.716
<v Speaker 2>non binary people in Asia, North and South America and Africa.

0:19:45.716 --> 0:19:50.116
<v Speaker 2>It's really broad and global. Yes, And in that study,

0:19:50.276 --> 0:19:52.796
<v Speaker 2>again among about two thousand people, there were only two

0:19:52.836 --> 0:19:58.676
<v Speaker 2>infections that occurred compared to nine infections among about a

0:19:58.676 --> 0:20:02.916
<v Speaker 2>thousand people who received the control so also quite a difference.

0:20:03.476 --> 0:20:07.076
<v Speaker 1>Yes, I mean, presumably the larger audience or the larger

0:20:07.196 --> 0:20:09.676
<v Speaker 1>patient population is the people who aren't taking oral prep

0:20:09.716 --> 0:20:13.316
<v Speaker 1>at all. Precisely, and you can't randomize ethically to that.

0:20:13.516 --> 0:20:15.076
<v Speaker 1>You can't have a control group where it's like we're

0:20:15.076 --> 0:20:16.556
<v Speaker 1>not going to give them anything and we're going to

0:20:16.556 --> 0:20:18.756
<v Speaker 1>see how they do. But in real life, that is

0:20:19.196 --> 0:20:21.876
<v Speaker 1>probably the population you're looking for.

0:20:21.796 --> 0:20:22.476
<v Speaker 2>Right exactly.

0:20:22.516 --> 0:20:26.756
<v Speaker 1>So okay, congratulations on the successful outcome of the trials.

0:20:27.076 --> 0:20:27.796
<v Speaker 1>Where are you now?

0:20:29.236 --> 0:20:32.716
<v Speaker 2>Oh so you know, bigger mind we talked about before.

0:20:32.796 --> 0:20:35.756
<v Speaker 2>You know, just because science can be the science may

0:20:35.796 --> 0:20:39.476
<v Speaker 2>be fantastic, you may have a great publication or a

0:20:39.516 --> 0:20:41.836
<v Speaker 2>great p value for science, it doesn't mean that people

0:20:41.876 --> 0:20:44.476
<v Speaker 2>actually get medicine. And so the medicine when the cover

0:20:44.556 --> 0:20:48.796
<v Speaker 2>has been submitted to regulatory agencies, because drug approvals.

0:20:48.276 --> 0:20:52.076
<v Speaker 4>Are a necessary step for people to receive them, and

0:20:52.116 --> 0:20:57.636
<v Speaker 4>that rigorous process is ongoing now and regulatory parentcies all

0:20:57.676 --> 0:20:58.356
<v Speaker 4>around the world.

0:20:58.436 --> 0:21:01.796
<v Speaker 2>From the beginning, the thought has been for loutic cover

0:21:01.876 --> 0:21:04.676
<v Speaker 2>that's a medicine that can have a global impact, and

0:21:05.156 --> 0:21:10.236
<v Speaker 2>then readying for being able to make it and distribute

0:21:10.236 --> 0:21:12.916
<v Speaker 2>it for people all around the world. As we have

0:21:12.956 --> 0:21:15.396
<v Speaker 2>been doing all of those steps, the dissemination of the science,

0:21:15.836 --> 0:21:21.116
<v Speaker 2>the regulatory submissions, we've been simultaneously making plans for global

0:21:21.156 --> 0:21:23.996
<v Speaker 2>access particularly access for low and lower middle income countries,

0:21:24.036 --> 0:21:26.276
<v Speaker 2>and that part of the story is as important as

0:21:26.316 --> 0:21:30.996
<v Speaker 2>everything else because success for ending HIV is it has

0:21:31.036 --> 0:21:32.116
<v Speaker 2>to be a global success.

0:21:32.836 --> 0:21:35.236
<v Speaker 1>Yeah, so let's talk about that. I mean, there's obviously

0:21:35.836 --> 0:21:41.436
<v Speaker 1>an interesting history of getting HIV drugs to lower income

0:21:41.556 --> 0:21:44.476
<v Speaker 1>countries that largely has been a success. Right, people don't

0:21:44.476 --> 0:21:47.356
<v Speaker 1>talk about it that much anymore, but it's a good,

0:21:47.556 --> 0:21:52.556
<v Speaker 1>happy story. Ultimately, what's happening with Lena kapavir that in

0:21:52.596 --> 0:21:54.876
<v Speaker 1>that context, Yes, the the.

0:21:55.676 --> 0:21:57.716
<v Speaker 2>You know, we talked back about my earlier history and

0:21:57.756 --> 0:22:00.476
<v Speaker 2>I remember well when there were no medicines in lower

0:22:00.516 --> 0:22:03.876
<v Speaker 2>middle income countries and then when there was, and that

0:22:04.476 --> 0:22:07.356
<v Speaker 2>was a delay of years and years. And that's not

0:22:07.476 --> 0:22:10.956
<v Speaker 2>unique to HIV. That is for innovations and health in general,

0:22:10.956 --> 0:22:14.156
<v Speaker 2>that it can take years or decades for medicines to

0:22:14.236 --> 0:22:19.516
<v Speaker 2>make it from when they're discovered to even approval and

0:22:19.556 --> 0:22:26.676
<v Speaker 2>then availability in low income countries. For lenikapavier years ahead

0:22:26.716 --> 0:22:29.796
<v Speaker 2>of results, truly years ahead before we had results. We

0:22:29.796 --> 0:22:34.876
<v Speaker 2>were thinking about how we can compress that calendar, and

0:22:35.316 --> 0:22:40.316
<v Speaker 2>that included within weeks of the Purpose trials reading out

0:22:40.716 --> 0:22:44.556
<v Speaker 2>an announcement that we'd signed voluntary license agreements which are

0:22:44.676 --> 0:22:47.516
<v Speaker 2>which allow a generic manufacturer to make a version of

0:22:47.556 --> 0:22:50.836
<v Speaker 2>the medicine. So would volntarize de agreees with six generic

0:22:50.876 --> 0:22:56.356
<v Speaker 2>manufacturers covering one hundred and twenty countries low and lower

0:22:56.396 --> 0:22:59.516
<v Speaker 2>mediome countries to be able to make generic versions in

0:22:59.556 --> 0:23:02.956
<v Speaker 2>the medicines royalty free and no profit real that as

0:23:02.956 --> 0:23:05.716
<v Speaker 2>soon as they're able to, so as soon as they

0:23:05.876 --> 0:23:08.956
<v Speaker 2>can ramp up their technical capacity to be able to

0:23:08.956 --> 0:23:10.956
<v Speaker 2>make these medicines.

0:23:10.836 --> 0:23:13.916
<v Speaker 1>So it will be cheap for people in four parts

0:23:13.956 --> 0:23:16.276
<v Speaker 1>of the world. And what does that mean sub Saharan Africa,

0:23:16.476 --> 0:23:20.116
<v Speaker 1>parts of Asia exactly? What about well, what's it going

0:23:20.156 --> 0:23:22.356
<v Speaker 1>to cost in the US? And how does how does

0:23:22.396 --> 0:23:25.716
<v Speaker 1>like insurance work for PREP? Insurance cover PREP.

0:23:25.756 --> 0:23:28.596
<v Speaker 2>So insurance dots cover PREP in the United States. And

0:23:28.956 --> 0:23:34.156
<v Speaker 2>the CDC has done really extensive analysis yes, to summarize

0:23:34.196 --> 0:23:36.556
<v Speaker 2>a lot of really good signs there their conclusions that

0:23:36.796 --> 0:23:40.516
<v Speaker 2>access to PREP is not limited by insurance coverage, that

0:23:40.516 --> 0:23:42.756
<v Speaker 2>there are two thirds of people who could most benefit

0:23:43.076 --> 0:23:45.516
<v Speaker 2>using PREP. That's not for insurance reasons, that is for

0:23:45.876 --> 0:23:47.756
<v Speaker 2>all kinds of the other reasons that we talked about

0:23:47.916 --> 0:23:49.876
<v Speaker 2>of stigma and and I think that's a strategy looking

0:23:49.876 --> 0:23:52.396
<v Speaker 2>forward to to len ACAFA. It's not proved yet United States,

0:23:52.436 --> 0:23:55.996
<v Speaker 2>so there's not both insurance coverage and other things are

0:23:56.036 --> 0:23:59.836
<v Speaker 2>not said yet. Those don't happen until the FDA is

0:23:59.876 --> 0:24:03.036
<v Speaker 2>able to do their rigorous assessment about the efficating and

0:24:03.076 --> 0:24:03.996
<v Speaker 2>safety of the medicine.

0:24:04.556 --> 0:24:07.596
<v Speaker 1>So, Okay, you've been working on HIV for for a

0:24:07.596 --> 0:24:10.676
<v Speaker 1>long time now, right for deaths, And I'm curious when

0:24:10.716 --> 0:24:13.756
<v Speaker 1>you sort of take the long view and you step back,

0:24:14.516 --> 0:24:15.116
<v Speaker 1>what do you see?

0:24:15.996 --> 0:24:18.316
<v Speaker 2>Oh, you know, I have been doing this for a

0:24:18.356 --> 0:24:23.276
<v Speaker 2>long time, and what has always motivated me is you

0:24:23.316 --> 0:24:25.716
<v Speaker 2>know it is actually ending the epidemic.

0:24:25.756 --> 0:24:28.556
<v Speaker 1>When you say ending the epidemic, I mean like I

0:24:28.596 --> 0:24:32.116
<v Speaker 1>think of a vaccine and a global eradication campaign. Is

0:24:32.116 --> 0:24:33.716
<v Speaker 1>that what you mean when you say that.

0:24:34.396 --> 0:24:36.636
<v Speaker 2>I want to stop new infections. I want to be

0:24:36.636 --> 0:24:38.396
<v Speaker 2>able to stop my infections as much as we can.

0:24:38.756 --> 0:24:42.476
<v Speaker 2>I want to have treatments that are availed to every

0:24:42.516 --> 0:24:44.676
<v Speaker 2>person living with HIV that allow them to live a

0:24:44.676 --> 0:24:47.436
<v Speaker 2>full life, and as a result, turning off the tap

0:24:47.476 --> 0:24:51.396
<v Speaker 2>of new infections, treating effectively the infections that are existing,

0:24:52.556 --> 0:24:58.916
<v Speaker 2>then the public health emergency diminishes, and the cloud that

0:24:59.036 --> 0:25:00.196
<v Speaker 2>is ACHIV on the world.

0:25:04.476 --> 0:25:06.436
<v Speaker 1>We'll be back in a minute with the lighting round.

0:25:16.076 --> 0:25:19.716
<v Speaker 1>You have undergraduate degrees, as I understand it, in both

0:25:19.796 --> 0:25:24.356
<v Speaker 1>biochemistry and comparative religion. Which religions did you compare in

0:25:24.396 --> 0:25:24.996
<v Speaker 1>which one.

0:25:24.836 --> 0:25:27.476
<v Speaker 2>One one one?

0:25:28.276 --> 0:25:29.116
<v Speaker 1>Which one lost?

0:25:30.716 --> 0:25:33.316
<v Speaker 2>Now I have an undergraduator in comparative religion, which I love.

0:25:33.476 --> 0:25:37.156
<v Speaker 2>I love the interface of society and health, society and

0:25:37.796 --> 0:25:40.956
<v Speaker 2>person of religion. Degree was a great way to get out.

0:25:41.796 --> 0:25:44.076
<v Speaker 1>I mean, tell me one thing, like what were you

0:25:44.156 --> 0:25:45.076
<v Speaker 1>actually interested in?

0:25:45.156 --> 0:25:45.676
<v Speaker 2>What? What? Like?

0:25:45.716 --> 0:25:48.756
<v Speaker 1>What like? Tell me one thing you learned in studying

0:25:48.796 --> 0:25:49.556
<v Speaker 1>comparative religion.

0:25:50.716 --> 0:25:55.236
<v Speaker 2>Oh, I don't many things in comparive religion. I loved.

0:25:55.716 --> 0:25:58.796
<v Speaker 2>I love complicated religious texts on how societies have fought

0:25:58.836 --> 0:26:02.596
<v Speaker 2>through mystery in the world. I loved American religions because

0:26:02.676 --> 0:26:05.076
<v Speaker 2>there's so much variety in the United States and it

0:26:05.116 --> 0:26:08.796
<v Speaker 2>reflects a lot of the energy of the US for

0:26:08.876 --> 0:26:13.476
<v Speaker 2>you know, all different directions. I have dynamism of dynamism

0:26:13.676 --> 0:26:17.116
<v Speaker 2>of religion, and what religion says about society like still

0:26:17.116 --> 0:26:19.876
<v Speaker 2>influences my all of the stuff I do.

0:26:19.916 --> 0:26:23.516
<v Speaker 1>Now, what's your second least favorite virus?

0:26:24.516 --> 0:26:26.236
<v Speaker 2>Second least favorite virus?

0:26:26.676 --> 0:26:28.756
<v Speaker 1>I'm assuming HIV is your least favorite.

0:26:29.116 --> 0:26:32.076
<v Speaker 2>HIV is my well, HIV is my favorite book favorite.

0:26:32.756 --> 0:26:35.356
<v Speaker 1>There's two ways to frame it, right, favorite or least favorite,

0:26:35.436 --> 0:26:37.356
<v Speaker 1>kind of the same. What's the number two after HIV?

0:26:38.396 --> 0:26:38.636
<v Speaker 3>Oh?

0:26:39.396 --> 0:26:42.276
<v Speaker 2>Hmm? Flu? Like which one is? I want to like

0:26:42.356 --> 0:26:44.996
<v Speaker 2>white from the world. Flu would be great, big impact,

0:26:46.956 --> 0:26:52.876
<v Speaker 2>terrible viruses that would be like a Goola Marburg that

0:26:52.916 --> 0:26:56.276
<v Speaker 2>we'd love to that I'd love to see remove the world.

0:26:56.436 --> 0:27:00.036
<v Speaker 2>All the viral epatitis viruses there's multiples of them that

0:27:00.196 --> 0:27:03.516
<v Speaker 2>have tremendous prevalence in the world and don't get as

0:27:03.596 --> 0:27:07.836
<v Speaker 2>much attention but kill lots of people. Would be great

0:27:07.836 --> 0:27:08.356
<v Speaker 2>to eradic it.

0:27:09.516 --> 0:27:12.516
<v Speaker 1>How many papers have you co authored that quote, Tina Turner?

0:27:13.716 --> 0:27:18.156
<v Speaker 2>Oh, the quote one, Yes, there's one. There's there's one

0:27:18.156 --> 0:27:19.876
<v Speaker 2>with a what's love got to do with the title? Yes?

0:27:19.876 --> 0:27:21.796
<v Speaker 2>Which is about it was about like the motivations to

0:27:21.876 --> 0:27:24.156
<v Speaker 2>take prep right, the motivations to take prep are not

0:27:24.876 --> 0:27:27.676
<v Speaker 2>simply because someone waged their finger at you and said

0:27:27.676 --> 0:27:29.396
<v Speaker 2>take your medicine. Yeah. Love.

0:27:36.276 --> 0:27:41.036
<v Speaker 1>Jared Baton is senior vice president in virology at Kilead Sciences.

0:27:42.236 --> 0:27:44.236
<v Speaker 1>Just a quick note, we'll be off for the next

0:27:44.236 --> 0:27:46.356
<v Speaker 1>few weeks on a planned hiatus.

0:27:46.516 --> 0:27:47.316
<v Speaker 2>We'll be back soon.

0:27:47.996 --> 0:27:51.156
<v Speaker 1>Today's show was produced by Gabriel Hunter Chang, edited by

0:27:51.236 --> 0:27:55.396
<v Speaker 1>Lydia Jean Kott, and engineered by Sarah Buguer. I'm Jacob Goldstein.

0:27:55.596 --> 0:27:56.356
<v Speaker 2>Thanks for listening.